Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

A systematic review of the cardiotoxicity of methadone.

Alinejad S, Kazemi T, Zamani N, Hoffman RS, Mehrpour O.

EXCLI J. 2015 May 5;14:577-600. doi: 10.17179/excli2015-553. eCollection 2015. Review.

2.

Presence or Absence of QTc Prolongation in Buprenorphine-Naloxone Among Youth With Opioid Dependence.

Poole SA, Pecoraro A, Subramaniam G, Woody G, Vetter VL.

J Addict Med. 2016 Jan-Feb;10(1):26-33. doi: 10.1097/ADM.0000000000000176.

3.

Methadone induced torsades de pointes and ventricular fibrillation: A case review.

Khalesi S, Shemirani H, Dehghani-Tafti F.

ARYA Atheroscler. 2014 Nov;10(6):339-42.

4.

Methadone, QTc prolongation and torsades de pointes: Current concepts, management and a hidden twist in the tale?

Mujtaba S, Romero J, Taub CC.

J Cardiovasc Dis Res. 2013 Dec;4(4):229-35. doi: 10.1016/j.jcdr.2013.10.001. Epub 2013 Nov 16. Review.

5.

Methadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem.

Vieweg WV, Hasnain M, Howland RH, Clausen T, Koneru JN, Kogut C, Crouse EL, Hancox JC, Fernandez A, Pandurangi AK.

Ther Adv Psychopharmacol. 2013 Aug;3(4):219-32. doi: 10.1177/2045125312469982.

6.

Double jeopardy.

Cullington D, Dunford N, Beer S, Hobson N, Chattopadhyay S, John J.

Indian Heart J. 2013 May-Jun;65(3):315-8. doi: 10.1016/j.ihj.2013.04.016. Epub 2013 Apr 19.

7.

Torsades de pointes associated with methadone and voriconazole.

Reinhold JA, Sanoski CA, Russo AM, Cooper JM, Spinler SA.

BMJ Case Rep. 2009;2009. pii: bcr07.2009.2119. doi: 10.1136/bcr.07.2009.2119. Epub 2009 Dec 22.

8.

QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel.

Martin JA, Campbell A, Killip T, Kotz M, Krantz MJ, Kreek MJ, McCarroll BA, Mehta D, Payte JT, Stimmel B, Taylor T, Haigney MC, Wilford BB; Substance Abuse and Mental Health Services Administration.

J Addict Dis. 2011 Oct;30(4):283-306. doi: 10.1080/10550887.2011.610710. Erratum in: J Addict Dis. 2012 Jan;31(1):91. Haigney, Mark C P [added].

9.

Stereoselective Inhibition of the hERG1 Potassium Channel.

Grilo LS, Carrupt PA, Abriel H.

Front Pharmacol. 2010 Nov 22;1:137. doi: 10.3389/fphar.2010.00137. eCollection 2010.

10.

Role of voltage-gated sodium, potassium and calcium channels in the development of cocaine-associated cardiac arrhythmias.

O'Leary ME, Hancox JC.

Br J Clin Pharmacol. 2010 May;69(5):427-42. doi: 10.1111/j.1365-2125.2010.03629.x. Review.

11.

Methadone deaths: risk factors in pain and addicted populations.

Modesto-Lowe V, Brooks D, Petry N.

J Gen Intern Med. 2010 Apr;25(4):305-9. doi: 10.1007/s11606-009-1225-0. Epub 2010 Jan 20. Review.

12.

A community-based evaluation of sudden death associated with therapeutic levels of methadone.

Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K.

Am J Med. 2008 Jan;121(1):66-71. doi: 10.1016/j.amjmed.2007.10.009.

13.

Case files of the Drexel University Medical Toxicology Fellowship: methadone-induced QTc prolongation.

Wong SC, Roberts JR.

J Med Toxicol. 2007 Dec;3(4):190-4. No abstract available.

14.

The successful use of parenteral methadone in a patient with a prolonged QTc interval.

Sekine R, Obbens EA, Coyle N, Inturrisi CE.

J Pain Symptom Manage. 2007 Nov;34(5):566-9. Epub 2007 Jul 5.

Supplemental Content

Support Center